Vanguard Global Advisers’s Rapport Therapeutics RAPP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$675K Buy
20,079
+2,839
+16% +$123K ﹤0.01% 1943
2026
Q2
$718K Hold
17,240
– – ﹤0.01% 1938
2026
Q1
$539K Buy
+17,240
New +$485K ﹤0.01% 2004

Other funds holding RAPP

Vanguard Global Advisers's RAPP Position: Q3 2026 in Review

Vanguard Global Advisers increased its Rapport Therapeutics (RAPP) stake by 16% in Q3 2026, buying an estimated $123K and bringing the position to 20,079 shares worth $675K. The position accounts for ﹤0.01% of the portfolio, ranked #1943.

Vanguard Global Advisers first reported a position in RAPP in Q1 2026 and has held it in 3 quarters since. The position peaked at $718K in Q2 2026. 169 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Vanguard Global Advisers held 20,079 shares of Rapport Therapeutics worth $675K as of Q3 2026.
  • Vanguard Global Advisers bought 2,839 Rapport Therapeutics shares in Q3 2026, an estimated $123K.
  • Rapport Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1943 holding.
  • Vanguard Global Advisers first reported a position in Rapport Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Rapport Therapeutics position peaked at $718K in Q2 2026.
  • 169 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.